This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pentaglobin
- DrugBank Accession Number
- DB15865
- Background
Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations.1 It is comprised of immunoglobulin G (IgG) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).3
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- IgM-enriched immunoglobulins
- IVIgGM
- External IDs
- Pentaglobin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Pentaglobin has potential antibacterial and immunomodulatory properties where, compared to immunoglobulin treatments without IgM, pentaglobin may have an increased ability to eliminate infectious pathogens . The IgM in the preparation plays a role in complement activation and neutralization of bacterial endo- and exotoxins.3 Pentaglobin is used as an adjuvant in treatment of severe bacterial infections while it is also investigated against peritonitis, sepsis, and COVID-19.2
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Pentaglobin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pentaglobin. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Pentaglobin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentaglobin. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Pentaglobin. Amivantamab The risk or severity of adverse effects can be increased when Pentaglobin is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Pentaglobin. Ansuvimab The risk or severity of adverse effects can be increased when Pentaglobin is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pentaglobin. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pentaglobin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 97794-27-9
References
- General References
- Neilson AR, Burchardi H, Schneider H: Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005 Sep;20(3):239-49. doi: 10.1016/j.jcrc.2005.03.003. [Article]
- Vaira M, Scuderi S, Costamagna D, Barone R, De Simone M: [Use of pentaglobin in the treatment of sepsis in the patient undergoing intraperitoneal hyperthermic chemotherapy]. Tumori. 2003 Jul-Aug;89(4 Suppl):296-7. [Article]
- National Cancer Institute: IgM-enriched Immunoglobulins (CUI CL563000) [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Neonatal Sepsis / Very Low Birth Weight Baby 1 4 Unknown Status Treatment Sepsis of the Newborn 1 3 Not Yet Recruiting Prevention Inflammation / Neonatal Early Onset Sepsis / Newborn, Infant, Disease / Very Low Birthweight Infants 1 3 Recruiting Treatment Hypoglobulinemia / Sepsis / Septic Shock 1 2 Completed Treatment Septic Shock / Severe Sepsis 1 2 Recruiting Treatment Septic Shock 1 2 Suspended Treatment Peritonitis / Sepsis 1 2, 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 Not Available Completed Not Available Respiratory Distress Syndrome, Adult / Septic Shock 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 21, 2020 13:56 / Updated at September 27, 2022 20:45